PLSE · Pulse Biosciences, Inc.

Track PLSE — free

$47.85 +0.83 (+1.77%) At close · Aug 20

Market Cap

$3.35B

71.32M

Up next

Next earnings call

Nov 2, 2026 Est · unconfirmed · in 10 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 6, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Ask ALVIS about this →

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 14.9 · calm Equity put/call 0.52

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +116%

above

Price vs 50-day avg +47%

above

RSI (14) 77

overbought

MACD trend Positive

52-week position 100%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +54%

trailing

6-month return +155%

trailing

YTD return +249%

this year

Relative strength +144%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $33 › 200d $22 — 50d above 200d

Institutional flow Accumulating

+10% holders QoQ · +22 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

4.18% of float · ▲ +3.2% MoM · 7.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

106 holders — near 3-yr high, broad support

Squeeze score 72

high risk · 0–100

Fundamentals

Fair

Free cash flow $-54.4M

Balance sheet $80.7M

net cash

Quant / Vol

risk profile

Very High

Volatility 88%

annualized · 1-yr

Max drawdown −37%

past year

ATR 5.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Prior guidance period ended · from the Earnings Call filed Sep 30, 2023

Cash usage · fourth quarter of 2023 $8M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+116% Bullish

Price vs 50-day avg

+47% Bullish

RSI (14)

77 Bearish

MACD trend

Positive Bullish

52-week position

100% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $33 › 200d $22 — 50d above 200d

Institutional flow Accumulating

+10% holders QoQ · +22 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

4.18% of float · ▲ +3.2% MoM · 7.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

106 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $13 Now $48 · 100% Range high $48

vs 200-day avg +116% vs 50-day avg +47%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Cash used in operating activities	$18.7M	Q2 2026	—

Non-GAAP Cost and expenses non-GAAP	37.86M	Six Months Ended June 30, 2026	—

Non-GAAP Cost of product revenue non-GAAP	571K	Six Months Ended June 30, 2026	—
Non-GAAP Net loss non-GAAP	-35.84M	Six Months Ended June 30, 2026	—
Non-GAAP Research and development non-GAAP	25.2M	Six Months Ended June 30, 2026	—
Non-GAAP Selling, general and administrative non-GAAP	12.1M	Six Months Ended June 30, 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
PLSE Pulse Biosciences, Inc. this stock	$3.35B	+248.5%	—	—	4.2%
ISRG Intuitive Surgical Inc	$140.51B	-33.9%	+20.5%	45.7	1.9%
BDX Becton Dickinson & Co	$51.11B	—	+8.2%	—	3.7%
MDLN Medline Inc.	$44.58B	-22.4%	+11.5%	—	2.6%
ALC Alcon Inc	$35.25B	-7.5%	+10.5%	—	2.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

106

% held: 15.1%
Net QoQ: +2.9M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

109

View

Short & Settlement

Short Interest Rising

Shares short

3.0M

Days to cover: 7.0d
Change: +93.4K sh

View

Short Volume

Short vol %

57%

As of: Aug 20, 2026

Short Total

View

Fails to Deliver

FTD shares

233

Value: $8.2K
As of: Jul 31, 2026

View

Off-Exchange

Off-exchange %

43.6%

Week of: Jul 13, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$350.0K

Net income (FY): $-72.8M

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Aug 11, 2026
This year: 35

View

Proposed Sales

Value

$1.3M

Shares: 50.0K
Filed: Feb 12, 2026

View

Exempt Offerings

Offering

$50.0M

Filed: Jul 9, 2021

View

Earnings & Events

Earnings Calls

Last call

Aug 11, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
PLSE	+6.5%	+54.4%	+155.5%	+36.2%	+248.5%
SPY	-2.0%	+3.3%	+11.2%	+2.1%	+11.8%
vs SPY	+8.5%	+51.0%	+144.3%	+34.1%	+236.7%

Key facts CIK 1625101 CUSIP 74587B101 13F (30d) 101 filings 101 filers Visit website Investor relations

PLSE · Pulse Biosciences, Inc.

Price & Indicators

Up next

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance